Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Real-time Estimate Cboe BZX
Other stock markets
 19:55:24 07/05/2024 BST 		5-day change 1st Jan Change
43 USD +0.76% Intraday chart for Amphastar Pharmaceuticals, Inc. +4.98% -29.98%
04-30 FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
04-30 Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing
Sector Update: Health Care Stocks Advance Premarket Thursday
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
High-dose opioid reversal spray no better than lower dose in field, US study finds
Amphastar Pharmaceuticals Insider Sold Shares Worth $7,171,768, According to a Recent SEC Filing
Amphastar Pharmaceuticals Insider Sold Shares Worth $12,798,708, According to a Recent SEC Filing
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Insider Sold Shares Worth $223,446, According to a Recent SEC Filing
Amphastar Pharmaceuticals Insider Sold Shares Worth $262,500, According to a Recent SEC Filing
Amphastar Pharmaceuticals Q3 Adjusted Non-GAAP Earnings, Revenue Rise
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Amphastar Pharmaceuticals Prices $300 Million Senior Notes Offering
Amphastar Plans $300 Million Private Placement of Convertible Notes; Shares Slide After-Hours
Insider Sell: Amphastar Pharmaceuticals
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. News Amphastar Pharmaceuticals, Inc.
  5. Other languages